NASDAQ : ARTV
Artiva Biotherapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.19 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 204.85M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 204.85M |
| Enterprise Value | -134.70M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 48.89M |
| Shares Outstanding | 48.89M |
| Shares Change (YoY) | +22.89% |
| Shares Change (QoQ) | +59.71% |
| Owned by Insiders (%) | 4.64% |
| Owned by Institutions (%) | 40.63% |
| Float | 19.53M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.59 |
| P/TBV Ratio | 0.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 24.16 |
| Quick Ratio | 24.06 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -36.58% |
| Return on Assets (ROA) | -22.34% |
| Return on Invested Capital (ROIC) | -23.13% |
| Return on Capital Employed (ROCE) | -27.16% |
| Weighted Average Cost of Capital (WACC) | 18.13% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$789,748 |
| Employee Count | 115 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.68 |
| 52-Week Price Change | -4.56% |
| 50-Day Moving Average | 8.11 |
| 200-Day Moving Average | 8.03 |
| Relative Strength Index (RSI) | 20.59 |
| Average Volume (20 Days) | 1,128,331 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.74M |
| Short Previous Month | 2.30M |
| Short % of Shares Out | 5.60% |
| Short % of Float | 14.02% |
| Short Ratio (days to cover) | 5.00 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -96.15M |
| Pretax Income | -90.82M |
| Net Income | -90.82M |
| EBITDA | -93.46M |
| EBIT | -96.15M |
| Earnings Per Share (EPS) | -$3.21 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 349.39M |
| Total Debt | 9.85M |
| Net Cash | 339.55M |
| Net Cash Per Share | $6.95 |
| Equity (Book Value) | 347.50M |
| Book Value Per Share | 7.12 |
| Working Capital | 337.70M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -75.23M |
| Capital Expenditures | -1.68M |
| Depreciation & Amortization | 2.69M |
| Net Borrowing | -111,000 |
| Free Cash Flow | -76.91M |
| FCF Per Share | -$1.57 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -22.89% |
| Shareholder Yield | n/a |
| Earnings Yield | -76.57% |
| FCF Yield | -37.54% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $20.75 |
| Price Target Difference | 395.23% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |